GlassScriptPhysician profile
Stephen W Roderer
NPI 1225455249
$1,996.78
in general payments reported to CMS, 2019-2025
13 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.72 · 2021: $349 · 2022: $692 · 2023: $314 · 2024: $356 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $13.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.78 |
| Education | $13.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $437.56 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $323.12 | 2022-2023 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $234.22 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $232.74 | 2023-2024 | Tarpeyo |
| Amgen INC. | $161.22 | 2024-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $150.63 | 2023-2024 | Jynarque |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Pharmacosmos Therapeutics INC. | $101.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.72 | 2019 | |
| Medtronic, INC. | $89.01 | 2024 | Symplicity G3 |
| Akebia Therapeutics INC | $24.16 | 2025 | Vafseo |
| Mannkind Corporation | $14.34 | 2025 | |
| Travere Therapeutics, INC. | $13.78 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Roderer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.